HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, L.-M. Articles by Chao, J. Search for Related Content PubMed PubMed Citation Articles by Chen, L.-M. Articles by Chao, J. Social Bookmarking                      What's this?

Volume 271, Number 44, Issue of November 1, 1996 pp. 27590-27594
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Tissue Kallikrein-binding Protein Reduces Blood Pressure in Transgenic Mice

(Received for publication, June 12, 1996, and in revised form, August 9, 1996)

From the Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina 29425

The kallikrein-kinin system participates in blood pressure regulation. One of the kallikrein-kinin system components, kallikrein-binding protein, binds to tissue kallikrein and inhibits its activity in vitro. To investigate potential roles of rat kallikrein-binding protein (RKBP) in vivo, we have developed transgenic mice that express an RKBP gene under the control of the mouse metallothionein metal-responsive promoter. Expression of the transgene, RKBP, was detected in the liver, kidney, lung, heart, pancreas, salivary glands, spleen, brain, testis, and adrenal gland at the mRNA and protein levels. Systolic blood pressures of homozygous transgenic mice were 88.5 ± 0.8 mm Hg (mean ± S.E., n = 19, P < 0.001) for one line and 88.8 ± 1.6 mm Hg (mean ± S.E., n = 19, P < 0.001) for another, as compared with 100.5 ± 0.8 mm Hg (mean ± S.E., n = 18) for control mice. Direct blood pressure measurements of these transgenic mice through an arterial cannula showed similar reductions of blood pressure. Intravenous injection of purified RKBP into mice via a catheter produced a dose-dependent reduction of the mean arterial blood pressure. Our findings suggest that RKBP may function as a vasodilator in vivo, independent of regulating the activity of tissue kallikrein.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Q. Miao, J. Agata, L. Chao, and J. Chao Kallistatin is a new inhibitor of angiogenesis and tumor growth Blood, October 16, 2002; 100(9): 3245 - 3252. [Abstract] [Full Text] [PDF]

				V. Thongboonkerd, E. Gozal, L. R. Sachleben Jr., J. M. Arthur, W. M. Pierce, J. Cai, J. Chao, M. Bader, J. B. Pesquero, D. Gozal, et al. Proteomic Analysis Reveals Alterations in the Renal Kallikrein Pathway during Hypoxia-Induced Hypertension J. Biol. Chem., September 13, 2002; 277(38): 34708 - 34716. [Abstract] [Full Text] [PDF]

				H. C. HATCHER, N. M. WRIGHT, J. CHAO, L. CHAO, and J.-X. MA Kallikrein-binding protein is induced by growth hormone in the dwarf rat FASEB J, October 1, 1999; 13(13): 1839 - 1844. [Abstract] [Full Text]